Compound C108 |
| Catalog No.GC43306 |
Compound C108 is an inhibitor of the GTPase-activating protein (SH3 domain)-binding protein 2 (G3BP2), which is involved in breast tumor initiation.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 15533-09-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Compound C108 is an inhibitor of the GTPase-activating protein (SH3 domain)-binding protein 2 (G3BP2), which is involved in breast tumor initiation. In a mouse xenograft model of breast cancer, compound C108 (1 µM for 24 hours) reduces the proportion of tumor-initiating cells approximately 10-fold compared with untreated cells. In MDA-MB-453 cells, and in the patient-derived xenograft cell line MAXF 401, it diminishes mammosphere formation.
Average Rating: 5 (Based on Reviews and 33 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *